• Home
  • Inside Kyverna
  • The Science
  • News
  • Careers
  • Contact
Kyverna Therapeutics, Inc.

News & Events

Press Releases

January 13, 2020

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

Media Inquiries

To learn more about Kyverna’s work developing cell therapy for inflammatory and autoimmune disease, please reach out to us at:
media@kyvernatx.com
kyverna_logo_inv

Links

  • Home
  • News
  • Inside Kyverna
  • Careers
  • The Science
  • Contact

About

Kyverna is a cell therapy company engineering and developing a new class of curative living medicines for inflammatory and autoimmune diseases. Using its SmarTcellTM approach which includes synReg-T cell and synNotch CAR-T technology platforms, Kyverna reprograms T cells to target and selectively suppress or eliminate autoreactive immune cells. The company’s goal is to develop therapies that are selective, potent and durable to tame autoimmunity.

FOLLOW US ON SOCIAL

©2020 Kyverna Therapeutics, Inc. All rights reserved.
  • Privacy Policy